Articles published by Ollin Biosciences, Inc.

Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026

Today 7:00 EDT

From Ollin Biosciences, Inc.

Via Business Wire

Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at Clinical Trials at the Summit 2026

June 02, 2026

From Ollin Biosciences, Inc.

Via Business Wire

Ollin Biosciences to Participate in Upcoming Investor Conferences

May 27, 2026

From Ollin Biosciences, Inc.

Via Business Wire

Ollin Biosciences to Participate in Two Upcoming Investor Conferences

April 08, 2026

From Ollin Biosciences, Inc.

Via Business Wire

Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

March 30, 2026

From Ollin Biosciences, Inc.

Via Business Wire

Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

January 08, 2026

From Ollin Biosciences, Inc.

Via Business Wire

Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology

September 17, 2025

From Ollin Biosciences, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.